Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | CYB5R3 | P00387 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | TAS2R38 | P59533 | 2/20 | 0.49 |
| ▸ | LPO | P22079 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.49 |
| ▸ | TPO | P07202 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | DAO | P14920 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzylthiouracil SCHEMBL815137 | 0.76 | SMN1; SMN2 (1.00) | SMN1; SMN2CYB5R3ALDH1A1CYP3A4TAS2R38 | |
| SCHEMBL30069796 | 0.72 | SMN1; SMN2 (0.59) | SMN1; SMN2CYB5R3ALDH1A1CYP3A4TAS2R38 | |
| SCHEMBL26440143 | 0.72 | SMN1; SMN2 (0.59) | SMN1; SMN2CYB5R3ALDH1A1CYP3A4TAS2R38 | |
| SCHEMBL14123256 | 0.70 | SMN1; SMN2 (0.60) | SMN1; SMN2CYB5R3ALDH1A1CYP3A4TAS2R38 | |
| SCHEMBL5907147 | 0.70 | L3MBTL1 (0.47) | ALDH1A1DAOARMMP1MMP2 | |
| SCHEMBL22800853 | 0.69 | NPC1 (0.40) | ALDH1A1DAOAR | |
| SCHEMBL14123294 | 0.69 | SMN1; SMN2 (0.68) | SMN1; SMN2CYB5R3ALDH1A1CYP3A4TAS2R38 | |
| SCHEMBL23160962 | 0.69 | LPO (0.71) | SMN1; SMN2CYB5R3ALDH1A1CYP3A4TAS2R38 | |
| SCHEMBL7490345 | 0.68 | PCSK9 (0.59) | — | |
| SCHEMBL6806240 | 0.68 | SMN1; SMN2 (0.41) | SMN1; SMN2CYB5R3ALDH1A1CYP3A4TAS2R38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106044-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines | IDENIX PHARMACEUTICALS INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20040092539-A1 | Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them | COLLA PAOLO LA (IT) | 2004-05-13 | — | — | US | disclosed |
| US-20030225114-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4- oxopyrimidines | IDENIX PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| US-6635636-B1 | Reverse transcriptase inhibitors; human immunodeficiency virus and acquired immune deficiency syndrome | IDENIX PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1343502-A2 | METHODS FOR INHIBITING THE TRANSMISSION OF HIV USING TOPICALLY APPLIED SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES | Idenix (Cayman) Limited (KY) | 2003-09-17 | — | — | EP | disclosed |
| US-6545007-B2 | Topically applying to the skin or epithelial tissue of a human an effective amount of a dihydro-alkyloxy-benzyl-oxopyrimidine compound for inhibiting sexual transmission of HIV | IDENIX (CAYMAN) LIMITED (KY) | 2003-04-08 | — | — | US | disclosed |
| US-20030008887-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines | IDENIX PHARMACEUTICALS INC. | 2003-01-09 | — | — | US | disclosed |
| WO-2002040021-A2 | METHODS FOR INHIBITING THE TRANSMISSION OF HIV USING TOPICALLY APPLIED SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES | IDENIX (CAYMAN) LIMITED (KY) | 2002-05-23 | — | — | WO | disclosed |
| EP-1098887-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Novirio Pharmaceuticals Limited (KY) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000003998-A1 | SUBSTITUTED 6-BENZYL-4-OXOPYRIMIDINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NOVIRIO PHARMACEUTICALS LIMITED (KY) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106044-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines | DUT, UNG, NUDT1 | SMN1; SMN2 1823/4885CYB5R3 2926/4885ALDH1A1 1149/4885 |
| US-20030008887-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrimidines | DUT, UNG, NUDT1 | SMN1; SMN2 1889/4885CYB5R3 2824/4885ALDH1A1 1104/4885 |
| US-20040092539-A1 | Substituted 6-benzyl-4-oxopyrimidines, process for their preparation and pharmaceutical compositions containing them | TYMP, UMPS, TYMS | SMN1; SMN2 2192/4885CYB5R3 2453/4885ALDH1A1 1185/4885 |
| US-20030225114-A1 | Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4- oxopyrimidines | DUT, UNG, NUDT1 | SMN1; SMN2 1889/4885CYB5R3 2824/4885ALDH1A1 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.